Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
Home Client Center Publications

Design, synthesis, and biological evaluation of potent PPARα/δ dual agonists for the treatment of nonalcoholic steatohepatitis. The PK studies, hERG studies, and Ames tests were conducted by Medicilon

2023-07-11
|
Page View：

Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPARα/δ are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPARα/δ dual agonists.

The pharmacokinetic studies were conducted by Medicilon.

The hERG channel inhibition studies were conducted by Medicilon.

The Ames tests were conducted by Medicilon.

40.pngReference:

Zhiqi Feng, et al. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2022 Feb 10;65(3):2571-2592. doi: 10.1021/acs.jmedchem.1c02002. 

NASHnonalcoholic-fatty-liver-diseaseNAFLDpharmacokinetichERGAmes-tests
Share：
Return
Relevant News
Discovery and synthesis of a new class of selective TNIK inhibitors and evaluation of their anti-colorectal cancer effects, the pharmacokinetic properties was carried out by Medicilon
2023-07-11
The Traf2- and Nck-interacting protein kinase (TNIK) is a downstream signal protein of the Wnt/β-catenin pathway and has been thought of as a potential target for the treatment of colorectal cancer. SAR analysis leads to the identification of a number of potent TNIK inhibitors with Compound 21k being the most active one. Preliminary assessment for the pharmacokinetic properties of Compound 21k was carried out through services provided by Medicilon.
SLL-1206 is a kappa opioid receptor agonist with substantially improved physicochemical and pharmacokinetic properties
2023-07-11
The search for selective kappa opioid receptor (κOR) agonists with an improved safety profile is an area of interest in opioid research. SLL-1206 is a κOR agonist with single-digit nanomolar activities. SLL-1206 exhibits substantially improved physicochemical and pharmacokinetic properties, and reduces central nervous system effects. The authors are grateful to Medicilon Preclinical Research LLC. for pharmacokinetic studies on SLL-1206.
SKLB-YTH-60 ameliorates inflammation and fibrosis in Bleomycin-induced lung fibrosis mouse models. The in vivo pharmacokinetic study of YTH‐60 was performed by Medicilon
2023-07-11
Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through computer-aided drug design, de novo synthesis and high-throughput screening. YTH-60 has obvious anti‐proliferative activity on fibroblasts and A549 cells. YTH-60 has an acceptable oral bioavailability and appropriate eliminated half-life time. The in vivo pharmacokinetic study of YTH‐60 was performed by Medicilon.
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->